Biotech Values

[DewDiligence]

AGN is sharply down on the failure to reduce debt by selling either of the two business units slated for divestiture:

https://finance.yahoo.com/news/botox-sales-power-allergans-profit-beat-forecast-raise-122924148--finance.html

Allergan has been shopping its women's health and infectious disease businesses since May, following a strategic review of the company undertaken in an effort to reverse a steep slide in its share price.

On call with analysts to discuss third quarter results, Chief Executive Officer Brent Saunders said early buyer interest for the units was below the price he believes they are worth.

"These are good businesses, right? We have always said that while we absolutely would like to sell these businesses, we need to make sure that we get the right price given the dilutive effect on a variety of our financial metrics," Saunders said.